Biomarkers, Endothelial Dysfunction, Inflammation, MINOCA, Myocardial Infarction
Conditions
Brief summary
Around 10% of patients with myocardial infarction (MI) present with nonobstructive coronary arteries (MINOCA) which pathophysiology is often uncertain. The aim of the study is to evaluate inflammation and endothelial dysfunction biomarkers in MINOCA patients during both acute and stable phases, comparing them with those with MI and obstructive coronary arteries (MICAD).
Detailed description
Prospective observational study in patients with Myocardial Infarction (MI) divided into two groups: MI with obstructive coronary arteries (MICAD) and MI with non-obstructive coronary arteries (MINOCA). Levels of interleukin-6, tumor necrosis factor-alpha, high-sensitivity C- reactive protein, and asymmetric dimethylarginine will be determined at three time points: within the 24 hours from the onset of pain, discharge, and two months after MI. The association of biomarkers, normalized by peak troponin value, with the risk of MINOCA will be evaluated using logistic regression.
Interventions
DIAGNOSTIC_TESTCoronariography
Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.
Sponsors
Hospital Universitario Getafe
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients admitted with Myocardial Infarction and undergo a coronariography * Patients must sign informed consent.
Exclusion criteria
* Patients who don´t sign informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Levels of interleukin-6 (pg/ml) and tumor necrosis factor-alpha (pg/ml) | At three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI. | Levels of interleukin-6 (pg/ml) and tumor necrosis factor-alpha (pg/ml) will be determined. |
| Levels of endhotelial disfunction biomarkers | At three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI. | Levels of asymmetric dimethylarginine will be determined |
| Levels of high-sensitivity C-reactive protein (mg/L) | t three time points: within the 24 hours from the onset of pain, on the 5th day of admission, and two months after MI. | Levels of high-sensitivity C-reactive protein (mg/L) will be determined. |
Countries
Spain
Contacts
Primary ContactMARIA JESUS ESPINOSA, MD
Backup ContactJOAQUIN ALONSO, PHD
Outcome results
None listed